Adma Biologics Inc. (NASDAQ:ADMA)’s share price rose 2.6% during trading on Friday . The company traded as high as $5.67 and last traded at $5.61, with a volume of 61,749 shares. The stock had previously closed at $5.47.

ADMA has been the subject of a number of recent research reports. Maxim Group cut Adma Biologics from a “buy” rating to a “hold” rating in a report on Monday, August 1st. Raymond James Financial Inc. cut Adma Biologics from a “strong-buy” rating to a “market perform” rating in a report on Monday, August 1st.

The company has a 50-day moving average price of $6.51 and a 200 day moving average price of $6.38. The company’s market capitalization is $72.29 million.

Adma Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Friday, August 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by $0.11. On average, equities analysts forecast that Adma Biologics Inc. will post ($1.67) earnings per share for the current year.

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.